McKinsey Health Institute recently released a 59-page report on global metabolic health — and the numbers are impossible to ignore.

Around 900 million adults worldwide are obese, and more than 20 chronic diseases, from diabetes to dementia, are directly linked to obesity. The economic impact is equally severe: $2.76 trillion in GDP could be wiped out every year by 2050 — a figure close to the UK’s total GDP in 2023.

And beyond the economics lies the human cost. McKinsey estimates that 6.5 billion years of life could be lost globally to preventable disease.

The weight-loss revolution

Obesity isn’t just shortening lives; it’s draining the global economy. As the world grapples with a metabolic health crisis, GLP-1 drugs such as Ozempic have emerged as the apparent saviours.

The early numbers are impressive: more than 20% bodyweight lost by a third of users, and a 135–250% increase in market cap for pharmaceutical companies producing the drugs.

But the McKinsey report cautions against seeing medication as a miracle fix.

“While many aspects of the mechanism of action of GLP-1 from the gut to the pancreas and brain have been studied, the research is
by no means comprehensive across all physiological systems. There are GLP-1 receptors in the kidney, in the lung, and throughout the immune and cardiovascular systems, meaning any of these organs could be affected by GLP-1, but the effects are not yet well understood. 

“GLP-1s cause loss of both fat mass and lean body mass. This could have implications, as muscle plays several important functions in the body, including strength, energy regulation, and metabolism.”

The long-term picture is also uncertain.

“There are unexpected effects emerging from the use of GLP-1s. There are many GLP-1 receptors throughout the body. It is possible that they could be affected in ways that are not yet understood. Further research will be required to understand the full impact of GLP-1 drugs on the body. There is inconclusive evidence on several secondary effects, such as psychiatric issues,24 thyroid cancer,25 and infertility.”

And even if the drugs prove safe, they don’t tackle the underlying causes — how we eat, move, and scroll our way into metabolic dysfunction.

A fork in the road

The report describes society as being at a fork in the road, with two distinct paths ahead.

Path One relies on pharmaceutical intervention — a future built on weight-loss drugs.
Path Two focuses on prevention and systemic change.

The difference in outcomes could not be clearer.

Pharma alone:
132 million additional healthy life years
$2.7 trillion in global GDP gains

Prevention and systemic change:
469 million additional healthy life years
$5.6 trillion in global GDP gains

As McKinsey notes, the second path is “more ambitious, more complex, and more challenging,” but the rewards — for both human and economic health — are vastly greater.

The innovators leading the way

Real change will not begin within the system. It will come from outside — from pioneering start-ups and individuals who take responsibility for their health.

These innovators are already building the tools for a new era of personalised and preventative healthcare:

• Neko Health — bringing full-body scans to the mainstream.
• Epic Life — developing a personalised health AI that analyses bloodwork without hallucinating.
• CardioSignal by Precordior — using mobile motion sensors to assess heart disease risk.
• StoreGene — offering affordable genomic sequencing for deeper biological insight.
• Viome — decoding the gut microbiome to reveal personal nutrition and supplement needs.
• Biolinq — creating a new kind of biowearable for metabolic health.

The path ahead

“The scale of the opportunity in metabolic health, in terms of healthy years lived, is enormous,” the report says. “The health benefit is between three and four times that of reducing obesity alone, and with a potential $5.65 trillion annual GDP uplift, representing 3 percent of total GDP (in 2050). Achieving this vision is a task on par with the boldest collective efforts to address complex global challenges.”

The choice is simple, but the implications are huge. The future of global health will depend on which path we take — and how soon we start walking it.